Recombinant Human MS4A1 protein(204-291 aa), GST-tagged
Cat.No. : | MS4A1-20H |
Product Overview : | Recombinant Human MS4A1 protein(204-291 aa), fused with N-terminal GST tag, was expressed in E. coli. |
- Specification
- Gene Information
- Related Products
- Download
Source : | E. coli |
Species : | Human |
Tag : | GST |
Protein length : | 204-291 aa |
Form : | The purified protein was Lyophilized from sterile PBS (58mM Na2HPO4,17mM NaH2PO4, 68mM NaCl, pH7.4). 5 % trehalose and 5 % mannitol are added as protectant before lyophilization. The elution buffer contain 100mM GSH. |
AASequence : | GIVENEWKRMCTRSKSNVVLLSAGE KNEQTIKMKEEIIELSGVSSQPKNE EEIEIIPVQEEEEEEAEINFPAPPQ EQESLPVENEIAP |
Purity : | 85%, by SDS-PAGE with Coomassie Brilliant Blue staining. |
Storage : | Short-term storage: Store at 2-8°C for (1-2 weeks). Long-term storage: Aliquot and store at -20°C to -80°C for up to 3 months, reconstitution with sterile water and addition of an equal volume of glycerol. Avoid repeat freeze-thaw cycles. |
Reconstitution : | Reconstitute at 0.25 μg/μl in 200 μl sterile water for short-term storage. After reconstitution with sterile water, if glycerol has no effect on subsequent experiments, it is recommended to add an equal volume of glycerol for long-term storage. |
Gene Name : | MS4A1 membrane-spanning 4-domains, subfamily A, member 1 [ Homo sapiens ] |
Official Symbol : | MS4A1 |
Synonyms : | MS4A1; membrane-spanning 4-domains, subfamily A, member 1; CD20; B-lymphocyte antigen CD20; B1; Bp35; MS4A2; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1; S7; CVID5; LEU-16; MGC3969; |
Gene ID : | 931 |
mRNA Refseq : | NM_021950 |
Protein Refseq : | NP_068769 |
MIM : | 112210 |
UniProt ID : | P11836 |
Products Types
◆ Recombinant Protein | ||
MS4A1-09F | Recombinant Ferret MS4A1 protein(Glu213-Pro297), His-tagged | +Inquiry |
MS4A1-22H | Recombinant Human MS4A1 Protein (T2-P297 end), N-8×His-Flag-TEV-tagged | +Inquiry |
MS4A1-0157H | Recombinant Human MS4A1 Protein (T2-P297 end), Flag, 8×His tagged | +Inquiry |
MS4A1-5732M | Recombinant Mouse MS4A1 Protein, His (Fc)-Avi-tagged | +Inquiry |
MS4A1-1135H | Recombinant Human MS4A1 Protein, His&GST-tagged | +Inquiry |
◆ Lysates | ||
MS4A1-819CCL | Recombinant Cynomolgus MS4A1 cell lysate | +Inquiry |
MS4A1-1542HCL | Recombinant Human MS4A1 cell lysate | +Inquiry |
MS4A1-1848FCL | Recombinant Ferret MS4A1 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewIts strong affinity allows for robust binding to target proteins, thereby enhancing the accuracy of analysis.
Surpassing expectations, it significantly amplifies the results of my research.
The operational guidelines for this reagent are readily comprehensible and accessible, facilitating seamless implementation of experiments, even for individuals lacking prior expertise.
Q&As (7)
Ask a questionMS4A1 expression is tightly regulated during different stages of B-cell development. It is absent in early B-cell progenitors and gradually increases during maturation. MS4A1 expression is upregulated upon B-cell activation and can be influenced by various cytokines and signaling pathways. This tightly controlled expression pattern ensures proper B-cell development, while aberrant regulation may contribute to B-cell disorders or malignancies.
MS4A1 expression levels have been explored as potential diagnostic or prognostic markers for certain B-cell disorders. Quantification of CD20 expression by immunohistochemistry or flow cytometry can aid in the diagnosis and classification of B-cell malignancies. Additionally, low CD20 expression levels have been associated with resistance to CD20-targeted therapies, serving as a prognostic indicator in B-cell lymphomas.
While CD20-targeted antibodies have revolutionized the treatment of B-cell malignancies, further therapeutic strategies are being explored. These include enhancing CD20 internalization, using antibody-drug conjugates, and developing novel targeted therapies based on the signaling pathways associated with MS4A1. Investigating these approaches may provide alternative treatments and improve outcomes for patients with B-cell disorders.
MS4A1 helps maintain immune tolerance by preventing the production of autoreactive B cells. It contributes to the elimination of self-reactive B cell clones through mechanisms such as antibody-dependent cellular cytotoxicity and antibody-mediated phagocytosis. MS4A1 dysregulation, however, can lead to the production of autoantibodies and the development of autoimmune diseases. Understanding the fine-tuned regulation of MS4A1's functions is essential for maintaining immune homeostasis and preventing autoimmunity.
MS4A1 interacts with multiple proteins, such as tetraspanins, Src-family kinases, and lipid rafts, which form a complex network involved in B-cell signaling. Upon ligand binding, MS4A1 activates intracellular signaling pathways, including PI3K/Akt and MAPK/ERK, which regulate B-cell survival, proliferation, and differentiation. Understanding these pathways and their crosstalk with MS4A1 can provide insights into B-cell activation and potential therapeutic targets.
The MS4A1 protein, also known as CD20, is a tetraspanin membrane protein found predominantly in B cells. It plays a crucial role in B-cell development, activation, and antibody production. Structurally, CD20 consists of four transmembrane domains and a large extracellular loop. Functionally, it regulates B-cell signaling by promoting calcium influx upon B-cell receptor activation, modulating cell cycle progression, and facilitating antibody-mediated cytotoxicity.
MS4A1 dysregulation has been implicated in B-cell malignancies, including non-Hodgkin lymphomas and leukemia. Increased expression or altered signaling of MS4A1 may promote survival and proliferation of malignant B cells. CD20-targeted therapies, such as monoclonal antibodies, have been successfully employed in treating B-cell malignancies, highlighting the significance of MS4A1 as a therapeutic target in these diseases.
Ask a Question for All MS4A1 Products
Required fields are marked with *
My Review for All MS4A1 Products
Required fields are marked with *
Inquiry Basket